⌘K
t
Oxford Biomedica plc granted its Site Head of UK Operations, Mark Caswell, an LTIP award of 53,724 Ordinary Shares on 22 November 2024. Concurrently, an RSU award over 23,352 shares, previously granted to Mr. Caswell on 3 October 2024, was cancelled. The new LTIP award was scaled back by 20% and is scheduled to vest on 3 October 2027, subject to performance conditions.
| Date | 22 Nov 2024 |
| Time | 14:56:45 |
| Category | Director/PDMR dealings |
| ID | 3867N |
Grant of options
Oxford, UK - 22 November 2024: Oxford Biomedica plc ("OXB" or the "Company"; LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the grant of an LTIP award under the OXB 2024 Long Term Incentive Plan ("LTIP") to Mark Caswell, Site Head of UK Operations.
In consideration of the grant of the award, an RSU award previously granted to Mark Caswell on 3 October 2024 has been cancelled.
As with the LTIP awards granted on 3 October 2024 and in line with best practice, the award was scaled back by 20%. The award is subject to the same performance conditions as the awards granted on 3 October 2024.
The award will "vest" on 3 October 2027 to the extent determined by reference to the assessment of the performance conditions and will be released at vesting.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form (1 of 2)
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Mark Caswell |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Site Head of UK Operations |
||||
|
b) |
Initial notification/ amendment |
Amendment |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Cancellation of RSU award over 23,352 shares granted under the Company's Long Term Incentive Plan. |
||||
|
c) |
Price(s) and volumes(s) |
RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
23,352
N/A |
||||
|
e) |
Date of the transaction |
2024-11-22 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
Notification of Dealing Form (2 of 2)
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Mark Caswell |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Site Head of UK Operations |
||||
|
b) |
Initial notification/ amendment |
Initial notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of 53,724 LTIP award over Ordinary Shares under the Company's Long Term Incentive Plan. |
||||
|
c) |
Price(s) and volumes(s) |
LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
53,724
N/A
|
||||
|
e) |
Date of the transaction |
2024-11-22 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
-Ends-
Enquiries:
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About OXB
OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.